CDK5 and Alzheimer disease: Abnormal regulation of Cdk5 by truncated activators (p25 and p29) contribute to neurodegeneration and has been implicated in Alzheimer’s diseases (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Niemann–Pick type C disease, and Ischemia [13,14].